Literature DB >> 19288452

Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy.

Martina Montagnana1, Giuseppe Lippi, Alessandro Albiero, Silvia Scevarolli, Gian Luca Salvagno, Massimo Franchi, Gian Cesare Guidi.   

Abstract

Matrix metalloproteinases (MMPs) are a family of zinc and calcium-dependent endopeptidases involved in remodeling and physiological homeostasis of extracellular matrix (ECM). The metalloproteinases activity is predominantly modulated by specific tissue inhibitors of matrix metalloproteinases (TIMPs). The balance between MMPs and TIMPs is likely to play an important role in remodeling uterine arteries in pregnancy, and it may represent means by which vasodilatation is maintained in later pregnancy. Moreover, increased levels of MMPs and in particular MMP-2 play a role in the vascular alterations induced by hypertension. The aim of this study was the evaluation of MMP-2 and -9, along with their inhibitors TIMP-1 and -2, in pre-eclamptic women compared with normotensive pregnancy and non-pregnant women. Fourteen pre-eclamptic women were compared with 37 normotensive women in different gestational age and 21 non-pregnant women. Multiplexed sandwich enzyme-linked immunosorbent assay was used to measure MMPs and TIMPs simultaneously. MMP-2 levels were significantly higher in pre-eclamptic women vs. both non-pregnant and physiologic pregnant women. MMP-9 concentrations were significantly higher in physiologic pregnant vs. non-pregnant women. The serum levels of TIMP-1 were significantly higher in pre-eclamptic vs. both non-pregnant and physiologic pregnant women. TIMP-2 values were higher in physiologic pregnant women and pre-eclamptic women vs. non-pregnant women. A positive correlation between MMP-9 values and gestational age was observed in normal pregnant women. Results of the present investigation confirm that MMP-2 and TIMP-1 values are significantly higher in preeclampsia. We confirm that the modification of the fine balance between MMPs and their inhibitors plays a greater role in the structural and functional vascular changes of women with complicated pregnancies. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19288452      PMCID: PMC6649012          DOI: 10.1002/jcla.20295

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  21 in total

Review 1.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 2.  Regulation of matrix biology by matrix metalloproteinases.

Authors:  Joni D Mott; Zena Werb
Journal:  Curr Opin Cell Biol       Date:  2004-10       Impact factor: 8.382

Review 3.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

4.  Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2.

Authors:  Muzahir H Tayebjee; Gregory Y H Lip; Andrew D Blann; Robert J Macfadyen
Journal:  Thromb Res       Date:  2005       Impact factor: 3.944

5.  Reduced expression of tissue inhibitor of metalloproteinase (TIMP)-2 in gestational trophoblastic diseases.

Authors:  Tomomitsu Okamoto; Rong Niu; Satoru Yamada; Masami Osawa
Journal:  Mol Hum Reprod       Date:  2002-04       Impact factor: 4.025

6.  A role for the 72 kDa gelatinase (MMP-2) and its inhibitor (TIMP-2) in human parturition, premature rupture of membranes and intraamniotic infection.

Authors:  E Maymon; R Romero; P Pacora; R Gomez; M Mazor; S Edwin; T Chaiworapongsa; J C Kim; B H Yoon; R Menon; S Fortunato; S M Berry
Journal:  J Perinat Med       Date:  2001       Impact factor: 1.901

7.  Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia.

Authors:  H Narumiya; Y Zhang; C Fernandez-Patron; L J Guilbert; S T Davidge
Journal:  Hypertens Pregnancy       Date:  2001       Impact factor: 2.108

8.  TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.

Authors:  M Mitchell Lindsay; Paul Maxwell; Francis G Dunn
Journal:  Hypertension       Date:  2002-08       Impact factor: 10.190

9.  Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling.

Authors:  Paul Schoenhagen; D Geoffrey Vince; Khaled M Ziada; Samir R Kapadia; Michael A Lauer; Timothy D Crowe; Steven E Nissen; E Murat Tuzcu
Journal:  Am J Cardiol       Date:  2002-06-15       Impact factor: 2.778

10.  Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.

Authors:  Wan-Uk Kim; So-Youn Min; Mi-La Cho; Kyung-Hee Hong; Yong-Joo Shin; Sung-Hwan Park; Chul-Soo Cho
Journal:  Arthritis Res Ther       Date:  2004-11-10       Impact factor: 5.156

View more
  39 in total

1.  DNA methylation profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsia.

Authors:  Ryan Kc Yuen; Maria S Peñaherrera; Peter von Dadelszen; Deborah E McFadden; Wendy P Robinson
Journal:  Eur J Hum Genet       Date:  2010-05-05       Impact factor: 4.246

2.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

4.  Candidate Gene and MicroRNA Expression in Fetal Membranes and Preterm Delivery Risk.

Authors:  Daniel A Enquobahrie; Mark Hensley; Chunfang Qiu; Dejene F Abetew; Karin Hevner; Mahlet G Tadesse; Michelle A Williams
Journal:  Reprod Sci       Date:  2015-10-27       Impact factor: 3.060

5.  Contribution of TIMP3 polymorphisms to the development of preeclampsia in Han Chinese women.

Authors:  Changlong Guo; Xiaofang Cao; Qidi Wang; Guangyu Wang; Lisha An; Meng Du; Yue Qiu; Ying Yang; Hui Li; Yuting Wang; Shuo Wang; Xingyu Wang; Xu Ma
Journal:  J Assist Reprod Genet       Date:  2015-08-25       Impact factor: 3.412

Review 6.  Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Sajjadh M J Ali; Raouf A Khalil
Journal:  Expert Opin Ther Targets       Date:  2015-08-17       Impact factor: 6.902

Review 7.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

8.  Impact of silencing MMP9 gene on the biological behaviors of trophoblasts.

Authors:  Jianying Luo; Fuyan Qiao; Xianghua Yin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-04-20

9.  Trophoblast survival signaling during human placentation requires HSP70 activation of MMP2-mediated HBEGF shedding.

Authors:  Chandni V Jain; Philip Jessmon; Charbel T Barrak; Alan D Bolnick; Brian A Kilburn; Michael Hertz; D Randall Armant
Journal:  Cell Death Differ       Date:  2017-07-21       Impact factor: 15.828

Review 10.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.